Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Paradigm Biopharmaceuticals ( (AU:PAR) ).
Paradigm Biopharmaceuticals has disclosed a change in director Matthew Fry’s interests, reporting the lapse of 354,958 listed options exercisable at $0.65 that expired on 11 February 2026. Following the lapse, Fry continues to hold 1,419,830 fully paid ordinary shares, with no consideration involved in the change and no trading during a closed period, indicating a routine update to the company’s director interest register without immediate operational impact.
The announcement reflects ongoing compliance with ASX listing rules and the Corporations Act, ensuring transparency around director holdings for investors and regulators. While the lapse slightly reduces Fry’s potential future equity exposure, it does not alter the company’s existing share count and primarily serves to keep the market accurately informed about board-level securities positions.
The most recent analyst rating on (AU:PAR) stock is a Hold with a A$0.27 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Limited is an Australian biopharmaceutical company listed on the ASX. The company focuses on developing and commercialising therapies, with its capital structure including fully paid ordinary shares and listed options, which are actively monitored and disclosed under Australian securities regulations.
YTD Price Performance: -14.71%
Average Trading Volume: 900,270
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$127.4M
For an in-depth examination of PAR stock, go to TipRanks’ Overview page.